NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Innospera Pharma Inc.

Innospera Pharma Inc.

Private
MontrealHealthcare & Life Scienceshttps://www.innospera.com/

Last Round

Seed

May 5, 2025

Total Funding Raised

$5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Innospera Pharma Inc. is a biotechnology company that develops small-molecule GPCR modulators for chronic inflammatory, metabolic, and fibrotic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug developmentbiotechclinical stagetherapeutic productsdrug discoverylicensing agreementclinical trialsbiopharmabuild-to-buypharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Innospera Pharma Inc. Comparables

Compare Innospera Pharma Inc. with similar companies based on industry and business-model similarity.

Innospera Pharma Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Liminal BioSciences Inc.
83%
Galapagos NV
74%
Structure Therapeutics
74%

Innospera Pharma Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 5, 2025

Key People

Founding team and executive leadership

François Ravenelle

President And Chief Executive Officer

Executive Team

Innospera Pharma Inc. Investors

Notable investors and investment history

Innospera Pharma Inc. investors
InvestorRounds
Investissement QuébecSeed
Bastien Family OfficeSeed
Investissement QuébecSeed
Anges QuebecSeed
Seido CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 155% MoM.

  • Jun 10, 2025

    Dr. Glenn Crater appointed as the new Chief Medical Officer.

Innospera Pharma Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Innospera Pharma Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Innospera Pharma Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMontreal
Employee Range11
Year Founded2025
Last FundingMay 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.